Visanu Wanchai, Ph.D. Visanu Wanchai, Ph.D., is a postdoctoral fellow with the UAMS College of Medicine. He earned his doctorate in biomedical informatics from UAMS in 2020 and joined the Myeloma Center in 2022. His focus is developing leading-edge computational tools and employing high-performance computing techniques for single cell analysis to investigate key genes and…
Bispecific BCMA/CD24 CAR T cells control multiple myeloma growth Nature Communications January 2024 Primary authors: Fumou Sun, Ph.D.; Yan Cheng, Ph.D. Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment strategy with high response rates in myeloma. However, durable cures following anti-BCMA CAR T-cell treatment of myeloma…
A strength of the University of Arkansas for Medical Sciences (UAMS) Myeloma Center is the variety of strategies utilized to obtain the best outcome for the patient. The center’s hospitalists are an important part of that process. The term “hospitalist” was coined in 1996 to describe physicians who only see patients in a hospital, typically…
Alan Stephenson has taken his myeloma diagnosis and turned it into a positive for himself and others in this situation. “One of the reasons I’m passionate about being an advocate is to let people know what to expect. The fear of the unknown is often a lot more than what you actually face,” he said….
Myeloma patients face several issues, one being compromised immune systems that make them more prone to infection. The UAMS Division of Infectious Diseases plays an important role in ensuring patients are in the best position to continue their cancer treatment. Under the direction of Michael Saccente, M.D., the Division of Infectious Diseases is part of…
By Frits van Rhee, M.D., Ph.D. Castleman disease was first described in 1954 by Benjamin Castleman, M.D., longtime chief of the Division of Anatomic Pathology at Massachusetts General Hospital in Boston. Patients with Castleman disease have enlargement of one or more lymph node areas. Patients who have the disease in one area, unicentric Castleman disease,…
Jeff Williams maintains a basic approach to living with multiple myeloma. “Get as much exercise as possible,” he said. “I work about a mile from a YMCA. I stay in shape. It has to be a habit. If you go long enough, it will become a habit. Resistance training builds bone density.” Williams, 66, is…
In his 11th year with the Myeloma Center at the University of Arkansas for Medical Sciences (UAMS), Sharmilan Thanendrarajan, M.D., Ph.D., knew he wanted to be a physician at a young age. “When I was in high school, I liked biology, chemistry and physics and decided to go in that direction,” said Thanendrarajan, an associate…
At the UAMS Myeloma Center, Fenghuang (Frank) Zhan, M.D., Ph.D., knows that research plays an immensely important role in the fight against multiple myeloma. Numerous federal grants allow the center’s director of research and his team to continue to advance and improve treatments, benefitting myeloma patients around the world. The latest is a $1.1 million…
Multiple myeloma treatment is advancing with the advent of bispecific antibody drugs, which use the patient’s T cells to fight the disease. Myeloma Center physicians and researchers Carolina Schinke, M.D., and Samer Al Hadidi, M.D., M.S., are leading clinical trials exploring combinations of these novel therapies. Schinke’s trial is studying the effects of using teclistamab…